

Treatment Emergent AEs by System Organ Class

System Organ Class	Placebo N = 86¹	Xanomeline High Dose N = 72¹	Xanomeline Low Dose N = 96¹
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	21 (24%)	36 (50%)	51 (53%)
GASTROINTESTINAL DISORDERS	17 (20%)	19 (26%)	15 (16%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	20 (23%)	39 (54%)	39 (41%)
CARDIAC DISORDERS	12 (14%)	14 (19%)	14 (15%)
INFECTIONS AND INFESTATIONS	16 (19%)	13 (18%)	9 (9.4%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	8 (9.3%)	10 (14%)	9 (9.4%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	4 (4.7%)	7 (9.7%)	7 (7.3%)
RENAL AND URINARY DISORDERS	4 (4.7%)	3 (4.2%)	3 (3.1%)
EYE DISORDERS	2 (2.3%)	1 (1.4%)	2 (2.1%)
METABOLISM AND NUTRITION DISORDERS	6 (7.0%)	2 (2.8%)	1 (1.0%)
PSYCHIATRIC DISORDERS	10 (12%)	7 (9.7%)	11 (11%)
INVESTIGATIONS	10 (12%)	5 (6.9%)	7 (7.3%)
SURGICAL AND MEDICAL PROCEDURES	2 (2.3%)	2 (2.8%)	1 (1.0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	4 (4.7%)	5 (6.9%)	5 (5.2%)
NERVOUS SYSTEM DISORDERS	8 (9.3%)	23 (32%)	22 (23%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (2.3%)	1 (1.4%)	0 (0%)
VASCULAR DISORDERS	3 (3.5%)	1 (1.4%)	3 (3.1%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	0 (0%)	2 (2.8%)	1 (1.0%)
EAR AND LABYRINTH DISORDERS	1 (1.2%)	1 (1.4%)	2 (2.1%)

¹ n (%)

System Organ Class	Placebo N = 86¹	Xanomeline High Dose N = 72¹	Xanomeline Low Dose N = 96¹
HEPATOBILIARY DISORDERS	1 (1.2%)	0 (0%)	0 (0%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0 (0%)	1 (1.4%)	2 (2.1%)
SOCIAL CIRCUMSTANCES	0 (0%)	1 (1.4%)	0 (0%)
IMMUNE SYSTEM DISORDERS	0 (0%)	0 (0%)	1 (1.0%)

¹ n (%)